Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
212
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib

Alejandro Garcia-HortonMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaORCID Iconhttps://orcid.org/0000-0003-0579-6709View further author information
ORCID Icon,
Elliot SmithMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaView further author information
,
Dawn MazeMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaView further author information
,
Caroline McNamaraMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaView further author information
,
Hassan SibaiMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaView further author information
&
Vikas GuptaMedical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaCorrespondence[email protected]
View further author information
Pages 495-497 | Received 07 Aug 2020, Accepted 24 Sep 2020, Published online: 14 Oct 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

We would like to thank Sarah Malik for her tireless effort and support with managing and the MPN database.

Author contributions

The study was conceived by AGH and VG. ES and AGH abstracted the data. DM, CM, HS, and VG provided study patients. AGH analyzed the data. AGH and VG drafted the manuscript. All authors reviewed and approved the final version of the manuscript.

Disclosure statement

VG has served on the advisory board of Novartis, Celgene, Pfizer, and Sierra Oncology; received research funding from Novartis and Incyte. All other authors do not have conflicts of interest to declare.

Additional information

Funding

This project was supported by a grant from the Elizabeth and Tony Comper Foundation and the Princess Margaret Cancer Center Foundation (VG).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.